Johanna Palmio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2252555/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Comprehensive transcriptomic analysis shows disturbed calcium homeostasis and deregulation of T lymphocyte apoptosis in inclusion body myositis. Journal of Neurology, 2022, 269, 4161-4173.	3.6	8
2	Editorial: Current and Future Developments in the Therapeutic Management of Neuromuscular Diseases. Frontiers in Neurology, 2021, 12, 835839.	2.4	0
3	Neurofilament Light Regulates Axon Caliber, Synaptic Activity, and Organelle Trafficking in Cultured Human Motor Neurons. Frontiers in Cell and Developmental Biology, 2021, 9, 820105.	3.7	23
4	Mutations in the J domain of DNAJB6 cause dominant distal myopathy. Neuromuscular Disorders, 2020, 30, 38-46.	0.6	20
5	New genotype-phenotype correlations in a large European cohort of patients with sarcoglycanopathy. Brain, 2020, 143, 2696-2708.	7.6	45
6	Expanding the importance of HMERF titinopathy: new mutations and clinical aspects. Journal of Neurology, 2019, 266, 680-690.	3.6	31
7	Novel mutation in <i>TNPO3</i> causes congenital limb-girdle myopathy with slow progression. Neurology: Genetics, 2019, 5, e337.	1.9	14
8	Actininopathy: A new muscular dystrophy caused by <i>ACTN2</i> dominant mutations. Annals of Neurology, 2019, 85, 899-906.	5.3	22
9	Myasthenic congenital myopathy from recessive mutations at a single residue in Na _V 1.4. Neurology, 2019, 92, e1405-e1415.	1.1	24
10	A novel COL6A2 mutation causing late-onset limb-girdle muscular dystrophy. Journal of Neurology, 2019, 266, 1649-1654.	3.6	10
11	Novel valosin-containing protein mutations associated with multisystem proteinopathy. Neuromuscular Disorders, 2018, 28, 491-501.	0.6	20
12	Variation in communication strategies in amyotrophic lateral sclerosis during a two-year follow-up. Speech, Language and Hearing, 2018, 21, 123-130.	1.0	1
13	Speech deterioration in amyotrophic lateral sclerosis (ALS) after manifestation of bulbar symptoms. International Journal of Language and Communication Disorders, 2018, 53, 385-392.	1.5	60
14	Absence of NEFL in patient-specific neurons in early-onset Charcot-Marie-Tooth neuropathy. Neurology: Genetics, 2018, 4, e244.	1.9	25
15	TIA1 variant drives myodegeneration in multisystem proteinopathy with SQSTM1 mutations. Journal of Clinical Investigation, 2018, 128, 1164-1177.	8.2	75
16	<i>CHCHD10</i> mutations and motor neuron disease: the distribution in Finnish patients. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 272-277.	1.9	19
17	Late-onset limb-girdle muscular dystrophy caused by GMPPB mutations. Neuromuscular Disorders, 2017, 27, 627-630.	0.6	11
18	Gluteus maximus hypertrophy: A diagnostic clue in four and a half LIM domain 1-mutated reducing body myopathy. Neuromuscular Disorders, 2017, 27, 962-963.	0.6	3

Johanna Palmio

#	Article	IF	CITATIONS
19	Predominantly myalgic phenotype caused by the c.3466G>A p.A1156T mutation in <i>SCN4A</i> gene. Neurology, 2017, 88, 1520-1527.	1.1	20
20	Targeted Next-Generation Sequencing Reveals Novel TTN Mutations Causing Recessive Distal Titinopathy. Molecular Neurobiology, 2017, 54, 7212-7223.	4.0	38
21	A novel FLNC frameshift and an OBSCN variant in a family with distal muscular dystrophy. PLoS ONE, 2017, 12, e0186642.	2.5	29
22	Unique Exercise Lactate Profile in Muscle Phosphofructokinase Deficiency (Tarui Disease); Difference Compared with McArdle Disease. Frontiers in Neurology, 2016, 7, 82.	2.4	9
23	Novel compound heterozygous mutation in <scp>SACS</scp> gene leads to a milder autosomal recessive spastic ataxia of Charlevoixâ€aguenay, <scp>ARSACS</scp> , in a Finnish family. Clinical Case Reports (discontinued), 2016, 4, 1151-1156.	0.5	12
24	CSF and plasma adipokines after tonic–clonic seizures. Seizure: the Journal of the British Epilepsy Association, 2016, 39, 10-12.	2.0	10
25	Oral motor functions, speech and communication before a definitive diagnosis of amyotrophic lateral sclerosis. Journal of Communication Disorders, 2016, 61, 97-105.	1.5	16
26	Diagnostically important muscle pathology in DNAJB6 mutated LGMD1D. Acta Neuropathologica Communications, 2016, 4, 9.	5.2	39
27	Mutations in <i>HSPB8</i> causing a new phenotype of distal myopathy and motor neuropathy. Neurology, 2016, 86, 391-398.	1.1	107
28	Re-evaluation of the phenotype caused by the common <i>MATR3</i> p.Ser85Cys mutation in a new family. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 448-450.	1.9	24
29	Spontaneous activity in electromyography may differentiate certain benign lower motor neuron disease forms from amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2015, 355, 143-146.	0.6	5
30	Novel mutations in DNAJB6 gene cause a very severe early-onset limb-girdle muscular dystrophy 1D disease. Neuromuscular Disorders, 2015, 25, 835-842.	0.6	35
31	PFKMgene defect and glycogen storage disease GSDVII with misleading enzyme histochemistry. Neurology: Genetics, 2015, 1, e7.	1.9	11
32	Borderlines between Sarcopenia and Mild Late-Onset Muscle Disease. Frontiers in Aging Neuroscience, 2014, 6, 267.	3.4	15
33	Hereditary myopathy with early respiratory failure: occurrence in various populations. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 345-353.	1.9	65
34	Screening for late-onset Pompe disease in Finland. Neuromuscular Disorders, 2014, 24, 982-985.	0.6	24
35	Immunological perspectives of temporal lobe seizures. Journal of Neuroimmunology, 2013, 263, 1-7.	2.3	30
36	An unusual phenotype of late-onset desminopathy. Neuromuscular Disorders, 2013, 23, 922-923.	0.6	9

JOHANNA PALMIO

#	Article	IF	CITATIONS
37	Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle muscular dystrophy. Nature Genetics, 2012, 44, 450-455.	21.4	226
38	Ubiquitin Carboxy-Terminal Hydrolase L1 (UCH-L1) is increased in cerebrospinal fluid and plasma of patients after epileptic seizure. BMC Neurology, 2012, 12, 85.	1.8	56
39	Four new Finnish families with LGMD1D; refinement of the clinical phenotype and the linked 7q36 locus. Neuromuscular Disorders, 2011, 21, 338-344.	0.6	22
40	Distinct distal myopathy phenotype caused by VCP gene mutation in a Finnish family. Neuromuscular Disorders, 2011, 21, 551-555.	0.6	58
41	Electroconvulsive therapy and biomarkers of neuronal injury and plasticity: Serum levels of neuron-specific enolase and S-100b protein. Psychiatry Research, 2010, 177, 97-100.	3.3	38
42	Cerebrospinal fluid tau as a marker of neuronal damage after epileptic seizure. Seizure: the Journal of the British Epilepsy Association, 2009, 18, 474-477.	2.0	50
43	Elevated serum neuron-specific enolase in patients with temporal lobe epilepsy: A video–EEG study. Epilepsy Research, 2008, 81, 155-160.	1.6	40
44	Increase in Plasma Proinflammatory Cytokines After Electroconvulsive Therapy in Patients With Depressive Disorder. Journal of ECT, 2008, 24, 88-91.	0.6	59
45	Changes in plasma amino acids after electroconvulsive therapy of depressed patients. Psychiatry Research, 2005, 137, 183-190.	3.3	37
46	Plasma and Cerebrospinal Fluid Amino Acids in Epileptic Patients. Neurochemical Research, 2004, 29, 319-324.	3.3	61
47	Normal CSF neuron-specific enolase and S-100 protein levels in patients with recent non-complicated tonic–clonic seizures. Journal of the Neurological Sciences, 2001, 183, 27-31.	0.6	50